[144] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cadrenal Therapeutics (CVKD) Form 144 notice: An insider proposes a Rule 144 sale of 419 common shares through Merrill Lynch with an aggregate market value of $5,869.50, planned for 09/29/2025. The shares were acquired as founders shares on 01/25/2022. The filing reports 2,046,854 shares outstanding for the issuer. The filer previously sold common stock in the past three months on 08/27/2025, 08/28/2025, 09/24/2025 and 09/25/2025 totaling 14,400 shares for $201,765.14 in gross proceeds. The notice includes the required signature attesting no undisclosed material information.

Positive

• None.

Negative

• Insider sales in past 3 months totaled 14,400 shares resulting in $201,765.14 gross proceeds, which may be observed by investors as notable insider selling activity.
• Upcoming sale, while small (419 shares, $5,869.50), continues a pattern of dispositions by the same person within the reported period.

Insights

Securities Analyst

TL;DR: Insider sale notice for 419 shares; materiality appears limited given total outstanding shares, but recent monthly selling is notable.

The filing documents a planned Rule 144 sale of 419 common shares acquired as founders shares on 01/25/2022, to be executed via Merrill Lynch on 09/29/2025. The issuer has 2,046,854 shares outstanding. Recent disposals by the same person amount to 14,400 shares in the past three months for $201,765.14 in gross proceeds. From a market-impact perspective this specific notice is small relative to the outstanding share base; however, the recent cadence of sales is a factual trend investors may track. No financial results, projections, or additional company disclosures are included in this filing.

Corporate Governance Expert

TL;DR: Routine Rule 144 disclosure consistent with insider liquidation; compliance elements present, no governance violations stated.

The form includes the required information: acquisition date and nature (founders shares, 01/25/2022), broker details, planned sale date, shares outstanding, and a signature representation concerning material nonpublic information. There is no allegation of wrongdoing or indication of a trading plan date under Rule 10b5-1 in the text provided. The filing therefore reads as a standard compliance disclosure of insider sales rather than a governance event triggering remediation or investigation.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	419	5869.5	2046854	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Founders Shares	Issuer			419	01/25/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/27/2025	3836	53455.56
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/28/2025	1193	16540.64
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/24/2025	2581	36108
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/25/2025	6790	95661.94

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Cadrenal Therapeutics (CVKD) report?

The filing reports a proposed Rule 144 sale of 419 common shares via Merrill Lynch on 09/29/2025; the shares were acquired as founders shares on 01/25/2022.

How many shares does Cadrenal Therapeutics have outstanding according to the filing?

The issuer reports 2,046,854 shares outstanding.

How much stock did the filer sell in the past three months and for what proceeds?

The filer sold 14,400 shares on four dates in Aug–Sep 2025, generating $201,765.14 in gross proceeds.

Who is the broker handling the proposed sale?

The proposed sale is to be handled by Merrill Lynch (address listed in the filing).

Does the filing indicate any undisclosed material information?

By signing the notice, the filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.